101 related articles for article (PubMed ID: 2849466)
21. The impact of bleomycin on retroperitoneal histology at post-chemotherapy retroperitoneal lymph node dissection of good risk germ cell tumors.
Cary KC; Pedrosa JA; Kaimakliotis HZ; Masterson TA; Einhorn LH; Foster RS
J Urol; 2015 Feb; 193(2):507-12. PubMed ID: 25254937
[TBL] [Abstract][Full Text] [Related]
22. Cisplatin, etoposide and continuous infusion bleomycin in patients with testicular germ cell tumors: efficacy and toxicity data from a retrospective study.
Curigliano G; Spitaleri G; Magni E; Lorizzo K; De Cobelli O; Locatelli M; Fumagalli L; Adamoli L; Cossu Rocca M; Verri E; De Pas T; Jereczek-Fossa B; Martinelli G; Goldhirsch A; Nolè F
J Chemother; 2009 Dec; 21(6):687-92. PubMed ID: 20071294
[TBL] [Abstract][Full Text] [Related]
23. Early resection of residual tumor during cisplatin, vinblastine, bleomycin combination chemotherapy in stage III and bulky stage II nonseminomatous testicular cancer.
Pizzocaro G; Salvioni R; Pasi M; Zanoni F; Milani A; Pilotti S; Monfardini S
Cancer; 1985 Jul; 56(2):249-55. PubMed ID: 2408728
[TBL] [Abstract][Full Text] [Related]
24. High-risk germ cell tumors in men. High response rate and severe toxicity with cisplatin, vinblastine, bleomycin, and etoposide.
Blayney DW; Goldberg DA; Leong LA; Margolin KA; Burke JS; Doroshow JH
Cancer; 1993 Apr; 71(7):2351-7. PubMed ID: 7680946
[TBL] [Abstract][Full Text] [Related]
25. Salvage chemotherapy with paclitaxel, ifosfamide, and cisplatin (TIP) in relapsed or cisplatin-refractory germ cell tumors.
Park S; Lee S; Lee J; Park SH; Park JO; Kang WK; Park YS; Lim HY
Onkologie; 2011; 34(8-9):416-20. PubMed ID: 21934340
[TBL] [Abstract][Full Text] [Related]
26. Vinblastine, actinomycin D, bleomycin, cyclophosphamide and cis-platinum for advanced germ cell testis tumors: Brazilian experience.
Srougi M; Simon SD; de Góes GM
J Urol; 1985 Jul; 134(1):65-9. PubMed ID: 2409300
[TBL] [Abstract][Full Text] [Related]
27. Prognostic impact of bleomycin pulmonary toxicity on the outcomes of patients with germ cell tumors.
Maruyama Y; Sadahira T; Mitsui Y; Araki M; Wada K; Tanimoto R; Kobayashi Y; Watanabe M; Watanabe T; Nasu Y
Med Oncol; 2018 Apr; 35(6):80. PubMed ID: 29700638
[TBL] [Abstract][Full Text] [Related]
28. Paclitaxel+BEP (T-BEP) regimen as induction chemotherapy in poor prognosis patients with nonseminomatous germ cell tumors: a phase II study.
Tryakin A; Fedyanin M; Kanagavel D; Fainstein I; Sergeev J; Polockij B; Matveev V; Zakharova T; Garin A; Tjulandin S
Urology; 2011 Sep; 78(3):620-5. PubMed ID: 21764427
[TBL] [Abstract][Full Text] [Related]
29. High-dose cis-platinum combination chemotherapy in advanced nonseminomatous malignant germ cell tumours with emphasis on nephrotoxicity.
Hall KS; Fosså SD; Aas M
Cancer Chemother Pharmacol; 1986; 18(1):74-7. PubMed ID: 2428537
[TBL] [Abstract][Full Text] [Related]
30. Long-term effects of chemotherapy in patients with testicular cancer.
Osanto S; Bukman A; Van Hoek F; Sterk PJ; De Laat JA; Hermans J
J Clin Oncol; 1992 Apr; 10(4):574-9. PubMed ID: 1372350
[TBL] [Abstract][Full Text] [Related]
31. Are 3 cycles of bleomycin, etoposide and cisplatin or 4 cycles of etoposide and cisplatin equivalent optimal regimens for patients with good risk metastatic germ cell tumors of the testis? The need for a randomized trial.
Culine S; Theodore C; Terrier-Lacombe MJ; Droz JP
J Urol; 1997 Mar; 157(3):855-8; discussion 858-9. PubMed ID: 9072585
[TBL] [Abstract][Full Text] [Related]
32. Sequential trials of cisplatin, vinblastine, and bleomycin and etoposide and cisplatin in disseminated nonseminomatous germ cell tumors of the testis with a good prognosis at a single institution.
Germá JR; Sagarra AF; Izquierdo MA; Seguí MA
Cancer; 1993 Feb; 71(3):796-803. PubMed ID: 7679314
[TBL] [Abstract][Full Text] [Related]
33. [Value of high-dose chemotherapy followed by bone marrow autograft in non-seminomatous germinal tumor with poor prognosis. Results of the combination of cisplatinum, etoposide and cyclophosphamide (PEC protocol)].
Baume D; Pico JL; Droz JP; Ostronoff M; Azab M; Gilles E; Ghosn M; Salloum E; Gouyette A; Beaujean F
Bull Cancer; 1990; 77(2):169-80. PubMed ID: 2156588
[TBL] [Abstract][Full Text] [Related]
34. Cisplatin, etoposide, bleomycin first-line therapy and early resection of residual tumor in far-advanced germinal testis cancer.
Pizzocaro G; Piva L; Salvioni R; Zanoni F; Milani A
Cancer; 1985 Nov; 56(10):2411-5. PubMed ID: 2412683
[TBL] [Abstract][Full Text] [Related]
35. Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial.
Horwich A; Sleijfer DT; Fosså SD; Kaye SB; Oliver RT; Cullen MH; Mead GM; de Wit R; de Mulder PH; Dearnaley DP; Cook PA; Sylvester RJ; Stenning SP
J Clin Oncol; 1997 May; 15(5):1844-52. PubMed ID: 9164194
[TBL] [Abstract][Full Text] [Related]
36. Etoposide and cisplatin with or without bleomycin as first-line chemotherapy for patients with small-volume metastases of testicular nonseminoma.
Peckham MJ; Horwich A; Blackmore C; Hendry WF
Cancer Treat Rep; 1985 May; 69(5):483-8. PubMed ID: 2408750
[TBL] [Abstract][Full Text] [Related]
37. Etoposide and very high dose cisplatin: salvage therapy for patients with advanced germ cell neoplasms.
Trump DL; Hortvet L
Cancer Treat Rep; 1985 Mar; 69(3):259-61. PubMed ID: 2983893
[TBL] [Abstract][Full Text] [Related]
38. Dose-response and dose-survival advantage for high versus low-dose cisplatin combined with vinblastine and bleomycin in disseminated testicular cancer. A Southwest Oncology Group study.
Samson MK; Rivkin SE; Jones SE; Costanzi JJ; LoBuglio AF; Stephens RL; Gehan EA; Cummings GD
Cancer; 1984 Mar; 53(5):1029-35. PubMed ID: 6198064
[TBL] [Abstract][Full Text] [Related]
39. A randomized trial of etoposide + cisplatin versus vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin in patients with good-prognosis germ cell tumors.
Bosl GJ; Geller NL; Bajorin D; Leitner SP; Yagoda A; Golbey RB; Scher H; Vogelzang NJ; Auman J; Carey R
J Clin Oncol; 1988 Aug; 6(8):1231-8. PubMed ID: 2457657
[TBL] [Abstract][Full Text] [Related]
40. Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group.
Schmoll HJ; Kollmannsberger C; Metzner B; Hartmann JT; Schleucher N; Schöffski P; Schleicher J; Rick O; Beyer J; Hossfeld D; Kanz L; Berdel WE; Andreesen R; Bokemeyer C;
J Clin Oncol; 2003 Nov; 21(22):4083-91. PubMed ID: 14568987
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
